3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
11
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Recurrence
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Lymphoma
1
Leukemia
1
Inflammatory Breast Neoplasms
1
Hemangiosarcoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Disease Progression
1
Disease
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Lobular
1
Breast Cancer With Brain Metastasis
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Bevacizumab
2
neratinib
1
brigatinib
1
Sufentanil
1
Radiosurgery
1
Mn-PyC3A
1
Losartan
1
HDAC-42
1
Cochlear Implants
1
Aspirin
1
((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroma, Acoustic
×
neratinib
×
1 year
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled